Mechanism of Zhilong Huoxue Tongyu Capsule in the Treatment of Atherosclerosis

Abstract

Abstract: Objective To explore the mechanism of Zhilong Huoxue Tongyu capsule in the treatment of atherosclerosis(AS) based on network pharmacology. Methods TCMSP, TCMID and other databases were devoted to screen out the active ingredients and targets of Zhilong Huoxue Tongyu capsule. The AS targets were obtained from GeneCard and DisgeNET databases, and the drug and disease intersection targets were selected. The PPI interaction network diagram of target was constructed by String11.0 database, and "drug-active ingredient-disease-target" network diagram, GO function and KEGG signaling pathway enrichment analysis were drawn by Cytoscape3.9.0 software. Results Zhilong Huoxue Tongyu capsule regulates AGE-rage, HIF-1, Apelin and other signaling pathways by acting on L6, TNF, VEGFA, CCl2, MMP9, NOS3 and other key targets through 58 active components of astragalus saponins, astragalus polysaccharide, kahamferol and quercetin. It ultimately affects inflammatory response, oxidative stress, angiogenesis, apoptosis and other biological processes to treat AS. Conclusion Zhilong Huoxue Tongyu capsule has the characteristics of multi-component, multi-target and multi-path mechanism in the treatment of AS.

Key words: zhilong huoxue tongyu capsule, atherosclerosis, mechanism of action, network pharmacology, molecular docking

摘要： 目的基于网络药理学方法探讨蛭龙活血通瘀胶囊治疗动脉粥样硬化(AS)的作用机制。方法采用多个中药及疾病数据库筛选蛭龙活血通瘀胶囊与动脉粥样硬化相关成分及靶点,取交集后,通过STRING 11.0数据库、Cytoscape 3.9.0软件构建PPI互作网络图和“药物-活性成分-疾病-靶点”网络图,并进行GO功能与KEGG信号通路富集分析。最后使用Auto Dock Tools 1.5.6软件进行分子对接。结果蛭龙活血通瘀胶囊通过多成分作用于L6、TNF、VEGFA、CCL2、MMP9、NOS3等多个核心靶点,调控AGE-RAGE、HIF-1、Apelin等多条信号通路,影响炎症反应、氧化应激、血管生成、细胞凋亡等生物过程治疗AS。结论蛭龙活血通瘀胶囊治疗AS具有多成分、多靶点、多通路的特点。

关键词: 蛭龙活血通瘀胶囊, 动脉粥样硬化, 作用机制, 网络药理学, 分子对接

CLC Number:

R284.2

GONG Li-yan, LI Shuang-yang, YANG Si-jin, BAI Xue. Mechanism of Zhilong Huoxue Tongyu Capsule in the Treatment of Atherosclerosis[J]. Journal of Chengde Medical University, 2022, 39(5): 371-375.

龚莉焰, 李双阳, 杨思进, 白雪. 蛭龙活血通瘀胶囊治疗动脉粥样硬化的作用机制[J]. 承德医学院学报, 2022, 39(5): 371-375.

References

[1] Chistiakov DA, Melnichenko AA, Grechko AV, et al.Potential of anti-inflammatory agents for treatment of atherosclerosis[J]. Exp Mol Pathol, 2018, 104(2): 114-124.
[2] 何松,苏悦,常永龙,等. 王清任《医林改错》活血化瘀思想探骊[J]. 福建中医药,2019,50(4):46-47.
[3] 任星,杨静,张菀桐,等. 基于数据挖掘和网络药理学的颈动脉粥样硬化用药规律及作用机制研究[J]. 中药新药与临床药理,2021,32(4):518-525.
[4] 李洋,刘炳,白雪,等. 益气祛风通络法对冠心病pci术后患者血管炎性反应和内皮功能的影响[J]. 广州中医药大学学报,2020,37(2):200-206.
[5] 耿路,张诗意,廖慧玲. 蛭龙活血通瘀胶囊拆方组分抗大鼠动脉粥样硬化及降血脂作用[J]. 西南医科大学学报,2021,44(3):222-227.
[6] 李亚琴,任维,罗钢,等. 蛭龙活血通瘀胶囊对缺血性脑卒中模型大鼠的作用及对脑皮层神经元线粒体的影响[J]. 中药药理与临床,2021:1-18.
[7] 禹博威,潘晓琼,陈君第霞,等. 黄芪多糖对糖尿病动脉粥样硬化大鼠糖脂代谢的影响及血管内皮保护机制[J]. 浙江中医药大学学报,2021,45(5):447-453.
[8] 徐锘,吴晓俊. 黄芪皂苷对神经系统疾病的药理作用研究进展[J]. 中国中药杂志,2021,46(18):4674-4682.
[9] 陈琼,黄水清. 黄芪总皂苷、当归挥发油对动脉粥样硬化ApoE~(-/-)小鼠脂质代谢的影响[J]. 中药新药与临床药理,2021,32(6):791-798.
[10] 徐索文,葛均波,翁建平. 内皮功能失调与泛血管疾病[J]. 中国科学技术大学学报,2021:1-16.
[11] 胡桂才,唐世英,李春华. 泡沫细胞与动脉粥样硬化[J]. 承德医学院学报,2008,(1):81-83.
[12] 陆忠杰,李盼. 老年冠心病患者他汀类药物不良反应特点及其诱发危险因素[J]. 医学综述,2021,(18):3722-3727.
[13] 赵诚. 二甲双胍联合格列齐特对2型糖尿病老年患者血糖控制及生活质量的影响[J]. 承德医学院学报,2018,35(4):306-308.
[14] Song PG; Fang Z; Wang HY,et al.Global and regional prevalence, burden, and risk factors for carotid atherosclerosis: a systematic review, meta-analysis, and modelling study[J]. The Lancet Global Health, 2020, 8(5): 721-729.
[15] 刘孟楠,任维,张伟,等. 蛭龙活血通瘀胶囊抑制nlrp3炎症小体活化抗u937巨噬细胞焦亡的机制研究[J]. 中药药理与临床,2020,36(6):156-161.
[16] 郑利珠,张诗意,廖慧玲. 蛭龙活血通瘀胶囊及其拆方对as大鼠et-1、No的影响[J].湖南中医杂志,2020,36(12):139-141,146.
[17] 龚磊,韦余,丁雁南,等. 黄芪总皂苷对脑出血大鼠脑组织病理学形态的影响[J]. 中国临床药理学杂志,2020,36(22):3713-3716.
[18] 胡妮娜,张晓娟. 黄芪的化学成分及药理作用研究进展[J]. 中医药信息,2021,38(1):76-82.
[19] 张雅雯,邵东燕,师俊玲,等. 山奈酚生物功能研究进展[J]. 生命科学,2017,29(4):400-405.
[20] XL Lu, CH Zhao, XL Yao, et al.Quercetin attenuates high fructose feeding-induced atherosclerosis by suppressing inflammation and apoptosis via ROS-regulated PI3K/AKT signaling pathway[J]. Biomedicine & Pharmacotherapy, 2017, 85: 658-671.
[21] HY Zhang, YZ Wang, ZY He. Glycine-Histidine-Lysine (GHK) Alleviates Neuronal Apoptosis Due to Intracerebral Hemorrhage via the miR-339-5p/VEGFA Pathway[J]. Frontiers in Neuroscience, 2018, 12: 644.
[22] 倪英群,方朝晖,施慧. 丹蛭降糖胶囊调控vegf信号通路促糖尿病大鼠血管新生的作用机制[J]. 北京中医药大学学报,2020,43(2):141-147.
[23] YY Zhang, YP Zhang. lncRNA ZFAS1 Improves Neuronal Injury and Inhibits Inflammation, Oxidative Stress, and Apoptosis by Sponging miR-582 and Upregulating NOS3 Expression in Cerebral Ischemia/Reperfusion Injury[J]. Inflammation, 2020, 43(4): 1337-1350.
[24] U Forstermann, WC Sessa. Nitric oxide synthases:regulation and function[J]. European Heart Journal, 2012, 33(7): 829-837.
[25] A Hernández-Aguilera, M Fibla, N Cabré, et al.Chemokine (C-C motif) ligand 2 and coronary artery disease:Tissue expression of functional and atypical receptors[J]. Cytokine, 2020, 126: 154923.
[26] 李胜男,王跃武,郭俊英,等. 朱日很滴丸对动脉粥样硬化模型兔mmp-9表达量的影响[J].西北药学杂志,2020,35(3):378-383.
[27] ES Jo, N Sp, DY Kang, et al. Sulfur Compounds Inhibit High Glucose-Induced Inflammation by Regulating NF-κB Signaling in Human Monocytes[J]. Molecules, 2020, 25(10): 2342.
[28] 杨超茅,杨志新,马晓玲. AGEs-RAGE信号通路在糖尿病肾病中的作用机制及中医药研究进展[J]. 中医学报,2019,34(9):1864-1868.
[29] H Patel, C Yong, A Navi, et al.Toll-like receptors 2 and 6 mediate apoptosis and inflammation in ischemic skeletal myotubes[J]. Vascular Medicine, 2019, 24(4): 295-305.
[30] 陈英,张文玲,黄涛,等. 炎症因子tnf-α、Il-6、Il-17与类风湿关节炎并发动脉粥样硬化的关系[J]. 免疫学杂志,2017,33(3):268-272.
[31] LM Senatus, SA Marie.The AGE-RAGE Axis:Implications for Age-Associated Arterial Diseases[J]. Frontiers in Genetics, 2017, 8: 187.
[32] S Liang, RH Ning, JY Zhang, et al. MiR-939-5p suppresses PM;-induced endothelial injury;targeting HIF-1α in HAECs[J]. Nanotoxicology, 2021, 15(5): 706-720.
[33] 李赫宁,陈临溪. Apelin/APJ系统:动脉粥样硬化治疗新靶点[J]. 中国动脉硬化杂志,2019,27(7):553-561.